Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.
Primmune Therapeutics Address
3210 Merryfield Row San Diego, CA
Primmune Therapeutics Email
Past Companies
Primmune TherapeuticsChief Business Officer and Co-founder